{"entity":{"id":"nct02779751","kind":"trial","name":"Abemaciclib with pembrolizumab in breast or lung cancer","aka":["A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer"],"tldr":"This early study tests abemaciclib with pembrolizumab in selected advanced breast and lung cancers. It examines safety and treatment activity.","summary":"This early study tests abemaciclib with pembrolizumab in selected advanced breast and lung cancers. It examines safety and treatment activity.\n\nInterventional study registered as NCT02779751, sponsored by Eli Lilly and Company. Registry phase: 1. Registry enrollment is 100 participants (estimated). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT02779751","url":"https://clinicaltrials.gov/study/NCT02779751"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT02779751"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["abemaciclib","anastrozole","pembrolizumab"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02779751","phase":"1","setting":"Advanced hormone receptor-positive, HER2-negative breast cancer or non-small cell lung cancer","sponsor":"Eli Lilly and Company","participation":[{"nct":"NCT02779751","source":"https://clinicaltrials.gov/study/NCT02779751","fetchedAt":"2026-10-10T20:54:19.775509Z","studySha256":"2651020b1b1128c9e0ee56df60a3db867453fee03b4000c7aa5b720ca865dff5","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-01-26","leadSponsor":"Eli Lilly and Company","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":100,"enrolmentType":"ESTIMATED","siteCount":24,"recruitingSiteCount":0,"countries":["Belgium","France","Italy","Spain","Taiwan","Turkey (Türkiye)","United States"]}],"started":"2016-11-14","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02779751/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"anastrozole","kind":"drug","name":"Anastrozole","route":"/drugs/anastrozole/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}